Filtrer vos résultats
- 2
- 2
- 2
- 1
- 1
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective studyJournal of Crohn's and Colitis, 2020, 14 (1), pp.S547. ⟨10.1093/ecco-jcc/jjz203.793⟩
Article dans une revue
hal-03551537v1
|
||
Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAIDJournal of Crohn's and Colitis, 2018, 12 (1), pp.S278
Article dans une revue
hal-03552412v1
|